Schulhoff & Co. Inc. Purchases Shares of 4,425 Solventum Co. (NYSE:SOLV)

Schulhoff & Co. Inc. acquired a new position in Solventum Co. (NYSE:SOLV) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 4,425 shares of the company’s stock, valued at approximately $234,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SilverOak Wealth Management LLC purchased a new position in shares of Solventum during the second quarter worth $1,198,000. Guardian Wealth Management Inc. purchased a new position in shares of Solventum during the 2nd quarter valued at about $95,000. Envestnet Asset Management Inc. acquired a new position in shares of Solventum in the 2nd quarter valued at about $6,747,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Solventum in the second quarter worth about $318,000. Finally, Dai ichi Life Insurance Company Ltd acquired a new stake in Solventum during the second quarter worth about $438,000.

Solventum Stock Up 2.0 %

SOLV opened at $70.00 on Friday. The firm’s fifty day moving average is $58.72. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a current ratio of 1.31, a quick ratio of 0.96 and a debt-to-equity ratio of 2.90.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.10. The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. The company’s revenue for the quarter was up .2% on a year-over-year basis. Equities research analysts expect that Solventum Co. will post 6.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. The Goldman Sachs Group boosted their price target on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. BTIG Research initiated coverage on shares of Solventum in a report on Thursday, September 5th. They set a “neutral” rating on the stock. Argus began coverage on shares of Solventum in a report on Monday, June 24th. They issued a “hold” rating for the company. Wells Fargo & Company lowered their target price on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, August 9th. Finally, Bank of America cut their price target on Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a research note on Tuesday, June 25th. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $58.25.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.